Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer

NCT00352872 · clinicaltrials.gov ↗
TERMINATED
Status
23
Enrollment
OTHER
Sponsor class

Stopped This study has been difficult to recruit.

Conditions

Sponsor

Indiana University